House Committee Reveals Drug Development Incentives, FDA Regulatory Overhaul
Tuesday, February 3, 2015
Source: FDA News
The House Energy & Commerce Committee that oversees the FDA is planning an overhaul of agency procedures to increase orphan drug development, streamline clinical trials oversight, give industry incentives to find new uses for old drugs and expand U.S. drug manufacturing.
The widely anticipated proposal was released last week by Rep. Fred Upton (R-Mich.), the committee chair, and committee member Diana DeGette (D-Colo). It grew out of hearings the committee held last year under its 21st Century Cures initiative, which sought suggestions for improving the process of developing and approving new medicines.